The Wegovy Price Increase in 2025: Separating Fact from Assumption

The myth: one dramatic price hike hit Wegovy in 2025

The most common assumption doing the rounds is that Wegovy simply became more expensive overnight, in the same way Mounjaro did when Eli Lilly revised its UK list price in September 2025. That framing fits one medicine but not the other. Novo Nordisk did not announce an equivalent single list-price uplift for Wegovy in 2025. What shifted instead was the broader private market: demand grew, supply pressures eased unevenly across dose levels, and providers adjusted their pricing structures at different points through the year. The result is that private Wegovy prices in the UK became harder to compare across providers, not uniformly higher.

It is also worth noting that Mounjaro's September 2025 list-price change was substantial (the highest-dose pen's list price reportedly rose from around £122 to around £330) and this story drew significant attention. Some of that attention spilled into searches about Wegovy, creating the impression of a parallel Wegovy event that did not happen in quite the same way. Whether Wegovy is still increasing in price is a separate question, and the honest answer depends on the dose and the provider.

If you want to track where things actually stand, the detailed history of Wegovy price changes sets out the sequence more carefully, and if you have seen recent headlines about costs coming down, the background to the Wegovy price decrease is worth reading alongside it. The short version: the 2025 narrative was real but messier than a single headline covers.

What a private Wegovy price actually includes, and what it often doesn't

When you see a monthly price quoted for Wegovy online, it is worth asking what that number is built from. Legitimate private treatment involves a clinical consultation, a prescription issued by a qualified prescriber, the medicine itself, and some form of aftercare. Not every provider bundles all of these into one figure. Consultation fees are sometimes charged separately. Prescription fees may appear at checkout. Delivery, which can add a meaningful amount for a medicine that needs refrigeration and careful handling, is occasionally billed on top. Dose-increase reviews (which matter because the titration schedule takes several months) may or may not be included.

This matters practically. A headline price that looks lower than a competitor's may represent a different set of services, or it may represent a lower-dose pen that is cheaper to produce. The NICE recommendation for semaglutide (Wegovy) outlines the clinical framework within which the medicine is intended to be used, and that framework assumes ongoing clinical oversight, not a one-off dispensing. The full Wegovy overview explains the dose titration schedule that makes that oversight necessary.

At nume, one transparent price covers the consultation, the prescription, the medicine, and free next-working-day delivery. There is no subscription and no auto-renewal. Every repeat is clinically re-reviewed before dispatch. We are not the cheapest option on the market (that is a deliberate position, not an oversight) because what the price includes matters as much as the number itself.

Will Wegovy become cheaper again in 2026?

This question has a more promising answer than many people expect. The MHRA approved a dedicated single-dose 7.2mg Wegovy pen in April 2026, which opens the possibility of higher maintenance doses for eligible patients without stacking multiple pens per week. Supply of Wegovy improved considerably through late 2024 and 2025 after earlier shortages, which historically helped stabilise private prices. Whether a Wegovy price drop in 2026 is likely is covered in more detail on its own page, but the supply picture is broadly more settled than it was.

What is harder to predict is how NHS rollout affects private pricing. As more patients access Wegovy through specialist weight management services under NICE TA875, private demand may shift, which could in turn influence what providers charge. None of this is guaranteed. If you are currently on treatment and wondering whether it is worth waiting for costs to fall, that is a conversation worth having with a prescriber who knows your progress, the evidence on what Wegovy typically achieves is relevant context for that decision.

The clinical team at nume reviews every repeat order individually; there is no pressure to continue if treatment is not suiting you, and no lock-in that makes leaving costly.

Why price is the wrong starting point for a prescription medicine

A lower monthly figure is not a reliable indicator of quality for a prescription-only medicine. The MHRA has documented large seizures of counterfeit and illicitly traded weight-loss pens, fake products that in some cases contained insulin rather than semaglutide. Sellers who compete solely on price often do so by removing the clinical infrastructure that protects patients: the prescriber assessment, the identity check, the verified supply chain. Ordering from a pharmacy you cannot verify on the GPhC register is a meaningful risk, not a theoretical one.

The right question is not "what is the cheapest Wegovy?" but "what am I actually getting, and from whom?" A small saving on a medicine that carries known side-effect risks, a titration schedule that requires monitoring, and a supply chain where fakes circulate is a saving that answers the wrong question entirely. If you are ready to find out whether you are clinically suitable, a free consultation with a real prescriber is the place to start. Before you do, you might find it useful to check the answers to questions we hear most often.